A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both beta-Cateninand RAS
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q2
- 저널
- CANCERS11(4) · 2019
- 피인용
- Web of Science 12Scopus 13
- FWCI (Scopus)
- 0.49
- JCR IF
- JCR 2018 6.162
- ISSN
- 2072-6694
저자
- Ryu, Won-Ji제1저자Translational Research Center for Protein Function Control, Yonsei University, Seoul, 03722, Korea
- Lee, Jae EunDepartment of Surgery, Yonsei University College of Medicine, Seoul, 03722, Korea
- Cho, Yong-HeeTranslational Research Center for Protein Function Control, Yonsei University, Seoul, 03722, Korea
- Lee, GunhoDepartment of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, 03722, Korea
- Seo, Mi-KyoungDepartment of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, 03722, Korea
- Lee, Sang-KyuTranslational Research Center for Protein Function Control, Yonsei University, Seoul, 03722, Korea
- Hwang, Jeong-HaTranslational Research Center for Protein Function Control, Yonsei University, Seoul, 03722, Korea
- 민도식Department of Molecular Biology, College of Natural Science, Pusan National University, Pusan, 46241, Korea
- Noh, Sung HoonDepartment of Surgery, Yonsei University College of Medicine, Seoul, 03722, Korea
- Paik, SoonmyungSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, 03722, Korea
- Kim, SangwooDepartment of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, 03722, Korea
- Cheong, Jae-Ho교신저자Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, Korea
- Choi, Kang-Yell교신저자Translational Research Center for Protein Function Control, Yonsei University, Seoul, 03722, Korea
초록
Treatment of advanced gastric cancer patients with current standard chemotherapeutic agents frequently results in resistance, leading to poor overall survival. However, there has been no success in developing strategies to overcome it. We showed the expression levels of both beta-catenin and RAS were significantly increased and correlated in tissues of 756 gastric cancer (GC) patients and tissues of primary- and acquired-resistance patient-derived xenograft tumors treated with 5-fluorouracil and oxaliplatin modulated with leucovorin (FOLFOX). On the basis of our previous studies, where small molecules to suppress colorectal cancer (CRC) via degrading both beta-catenin and RAS were developed, we tested the effectiveness of KYA1797K, a representative compound functioning by binding axin, in the growth of GC cells. The efficacy test of the drugs using gastric tumor organoids of Apc(1638N) mice showed that the CD44 and ALDH1A3 cancer stem cell markers were induced by FOLFOX, but not by KYA1797K. KYA1797K also efficiently suppressed tumors generated by re-engrafting the FOLFOX-resistant patient-derived xenograft (PDX) tumors, which also showed resistance to paclitaxel. Overall, the small-molecule approach degrading both beta-catenin and RAS has potential as a therapeutic strategy for treating GC patients resistant to current standard chemotherapies.
키워드
gastric cancerchemotherapy resistancedegradation of both beta-catenin and RASgastric cancer patient-derived xenograftHELICOBACTER-PYLORI INFECTIONGENEAPCLOCALIZATIONINSTABILITYEXPRESSIONMUTATIONPATHWAYCOLON
식별자
- Scopus EID
- 2-s2.0-85065388958
- WoS UID
- 000467773400064



로그인
연구물 목록으로